GLP-1s and PCOS: What the Research Shows

Polycystic ovary syndrome affects a large share of women of reproductive age, and one of its central, under-appreciated features is metabolic: insulin resistance sits at the heart of the condition for many. That metabolic link is exactly why GLP-1 drugs, which act powerfully on metabolism and weight, have become a subject of real interest in PCOS. The interest is justified. The evidence is still maturing.

Why the connection makes sense

PCOS is more than a reproductive disorder. Insulin resistance is common in the condition and appears to drive part of the hormonal disruption, including elevated androgens that contribute to irregular cycles, acne, and excess hair growth. Excess weight, where present, tends to worsen this loop.

GLP-1 receptor agonists improve insulin sensitivity, support weight loss, and improve several metabolic markers. On the logic of the disease, anything that meaningfully improves insulin resistance and weight could plausibly improve the downstream hormonal and reproductive features of PCOS.

What the research currently shows

The most rigorous summary to date is a 2026 systematic review and meta-analysis in the European Journal of Endocrinology, which pooled 11 randomized controlled trials of GLP-1 receptor agonists in women with PCOS. Its findings are a useful corrective to the hype:

• Weight and BMI fall, but modestly. Across the trials, GLP-1 treatment produced a mean BMI reduction of about −1.38 kg/m² (95% CI −2.39 to −0.38), rising to roughly −2.18 kg/m² versus placebo. The authors graded this as low-certainty evidence.
• Menstrual regularity may improve. Several included studies pointed toward more regular cycles, but the meta-analysis rated this as very low certainty.
• Testosterone and SHBG were not consistently reported as primary outcomes, so the pooled evidence on the hormonal features many patients care about most is thin.

Notably, the review found no trials of semaglutide or tirzepatide in PCOS, and none assessing mental-health outcomes or quality of life — sizeable gaps given how these drugs are actually used.

Outcome	Direction of effect	Certainty of evidence
BMI / weight	Reduced (~−1.4 to −2.2 kg/m²)	Low
Menstrual regularity	Possibly improved	Very low
Testosterone / SHBG	Inconsistently reported	Insufficient

The mechanistic case is genuinely strong, and the pooled trials lean in a favorable direction — but the meta-analysis grades the reproductive and metabolic benefits as low to very low certainty. A strong mechanism is a reason to investigate, not a substitute for outcome data.

Important open questions

• Fertility and pregnancy. GLP-1 drugs are generally not used when trying to conceive or during pregnancy, and timing around fertility goals matters. This is a conversation for a clinician, not a forum.
• Comparisons to existing options. Metformin and lifestyle interventions are established parts of PCOS management, and how GLP-1 drugs compare or combine with them is still being worked out.
• Durability. As with weight management generally, the benefits may depend on continued treatment.

A measured framing

PCOS care has historically been under-served, and it is understandable that a drug class delivering real metabolic benefit attracts hope. That hope is reasonable. It should still be paired with honesty that the dedicated PCOS evidence base is younger and thinner than the enthusiasm sometimes implies.

The takeaway

The biology connecting GLP-1 drugs and PCOS is sound, rooted in the shared territory of insulin resistance, and the pooled trials do show modest weight reduction and a hint of better menstrual regularity. But the best current meta-analysis grades that reproductive and metabolic benefit as low to very low certainty, and the newest drugs haven’t been studied in PCOS at all. For anyone with PCOS weighing these medications, the right next step is an individualized conversation with a clinician, not a conclusion drawn from the headline.

Sources

• GLP-1 receptor agonist treatment in women with polycystic ovary syndrome — a systematic review and meta-analysis (European Journal of Endocrinology, 2026)